CureVac N.V. Quarterly Research And Development Expense in EUR from Q1 2021 to Q4 2023

Taxonomy & unit
ifrs-full: EUR
Summary
CureVac N.V. quarterly/annual Research And Development Expense history and growth rate from Q1 2021 to Q4 2023.
  • CureVac N.V. Research And Development Expense for the quarter ending December 31, 2023 was €33.4M, a 20.8% increase year-over-year.
  • CureVac N.V. Research And Development Expense for the twelve months ending December 31, 2023 was €116M, a 85% increase year-over-year.
  • CureVac N.V. annual Research And Development Expense for 2023 was €116M, a 85% increase from 2022.
  • CureVac N.V. annual Research And Development Expense for 2022 was €62.6M, a 92.3% decline from 2021.
  • CureVac N.V. annual Research And Development Expense for 2021 was €816M, a 617% increase from 2020.
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 116M 33.4M +5.74M +20.8% Oct 1, 2023 Dec 31, 2023 20-F 2024-04-25
Q3 2023 110M 27.2M +14.7M +118% Jul 1, 2023 Sep 30, 2023 6-K 2023-11-14
Q2 2023 95.2M 30.9M +19.2M +165% Apr 1, 2023 Jun 30, 2023 6-K 2023-08-17
Q1 2023 76M 24.3M +13.5M +125% Jan 1, 2023 Mar 31, 2023 6-K 2023-05-30
Q4 2022 62.6M 27.6M Oct 1, 2022 Dec 31, 2022 20-F 2024-04-25
Q3 2022 12.5M Jul 1, 2022 Sep 30, 2022 6-K 2023-11-14
Q2 2022 11.6M Apr 1, 2022 Jun 30, 2022 6-K 2023-08-17
Q1 2022 10.8M -94.2M -89.7% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-30
Q1 2021 105M Jan 1, 2021 Mar 31, 2021 6-K 2022-05-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.